Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
Share Talk Weekly Stock Market News Review, Sunday 16th April 2023
Overall, the AIM All-Shares index had a positive week, with a more than 2% increase in share price, outperforming the FTSE 100. Friday’s closing bell, the FTSE 100 resumed its
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s
Share Talk Weekly Stock Market News Review, Sunday 2nd April 2023
The AIM-All Share Index, which rose by 0.6% to 804 points, made only slight gains across the wider market. However, the FTSE 100’s blue-chip companies surged 3% to 7,628 points
RNS Hotlist with Zak Mir: AJAX, POLB, GCAT, KR1, GDR, TOM, ORCA, GWMO, COBR & TM1
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Poolbeg Pharma PLC (AIM:POLB) Results for the year ended 31 December 2022
Significant milestones reached, well capitalised and positioned for future growth
Share Talk Weekly Stock Market News Review, Sunday 12th March 2023
As far as the small caps area is concerned, things remained tough work. Apart from bears enjoying the pain and occasionally the failures of others, to offset their own failings,
RNS Hotlist with Zak Mir: MARU, SNT, IES, PYC, VRS, POLB, HUM, IXI, 88E & CORA
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Poolbeg Pharma PLC (AIM:POLB) POLB 001 patent portfolio strengthened
POLB 001 patent portfolio strengthened through granting of US patent
Share Talk Weekly Stock Market News Review, Sunday 5th March 2023
London’s results season is still underway with life insurers Aviva and L&G, bookmaker Entain, cybersecurity specialist Darktrace, and sausage roll maker Greggs all set to release results this week.
Poolbeg Pharma Plc (AIM:POLB) Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza